RUBY insider filings

Rubius Therapeutics, Inc. — 39 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-02-27. Screen RUBY transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for RUBY between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Rubius Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2023-02-274Appelhans Dannielle — CEO and PresidentSale (S): 10,385 @ $0.13EDGAR
2023-02-014Appelhans Dannielle — CEO and PresidentOption exercise (M): 7,500 · Sale (S): 3,878 @ $0.25 · Option exercise (M): 7,500 (derivative) @ $0EDGAR
2023-02-014CAGNONI PABLO J — DirectorSale (S): 8,448 @ $0.25EDGAR
2023-01-314Turka Laurence A. — Chief Scientific OfficerOption exercise (M): 7,438 · Option exercise (M): 8,625 · Sale (S): 2,593 @ $0.24 · Option exercise (M): 7,438 (derivative) @ $0 · Option exercise (M): 8,625 (derivative) @ $0EDGAR
2023-01-314CAGNONI PABLO J — DirectorOption exercise (M): 21,250 · Option exercise (M): 25,000 · Sale (S): 7,240 @ $0.24 · Option exercise (M): 21,250 (derivative) @ $0 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2022-08-124Appelhans Dannielle — Chief Operating OfficerOption exercise (M): 12,500 · Sale (S): 5,737 @ $0.80 · Option exercise (M): 12,500 (derivative) @ $0EDGAR
2022-08-014Schaffert Susanne — DirectorGrant/award (A): 50,000 (derivative) @ $0EDGAR
2022-05-134Prener Anne — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-05-134Symonds Jonathan — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-05-134Holles Natalie C. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-05-134Sohn Catherine A. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-05-134Cuss Francis M — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-05-134Rosenblatt Michael — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-05-134Epstein David R — DirectorGrant/award (A): 499,762 (derivative) @ $0EDGAR
2022-05-134AFEYAN NOUBAR — Director, 10% ownerGrant/award (A): 25,000 (derivative) @ $0EDGAR
2022-04-224Epstein David R — DirectorPurchase (P): 30,000 @ $1.44EDGAR
2022-02-014Appelhans Dannielle — Chief Operating OfficerGrant/award (A): 125,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0EDGAR
2022-02-014Turka Laurence A. — Chief Scientific OfficerOption exercise (M): 7,438 · Sale (S): 2,517 @ $6.57 · Option exercise (M): 7,438 (derivative) @ $0 · Grant/award (A): 143,750 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0EDGAR
2022-02-014Carmona Jose — Chief Financial OfficerGrant/award (A): 143,750 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0EDGAR
2022-02-014Keson-Brookes Maiken — CLO & Corp. SecretaryOption exercise (M): 8,075 · Sale (S): 2,732 @ $6.57 · Option exercise (M): 8,075 (derivative) @ $0 · Grant/award (A): 143,750 (derivative) @ $0 · Grant/award (A): 34,500 (derivative) @ $0EDGAR
2022-02-014CAGNONI PABLO J — CEO and President, DirectorOption exercise (M): 21,250 · Sale (S): 6,730 @ $6.57 · Option exercise (M): 21,250 (derivative) @ $0 · Grant/award (A): 365,000 (derivative) @ $0 · Grant/award (A): 100,000 (derivative) @ $0EDGAR
2021-09-014Appelhans Dannielle — Chief Operating OfficerGrant/award (A): 150,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2021-05-134Prener Anne — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-05-134Symonds Jonathan — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-05-134Holles Natalie C. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-05-134Sohn Catherine A. — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-05-134Cuss Francis M — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-05-134Rosenblatt Michael — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-05-134Epstein David R — DirectorGrant/award (A): 27,919 (derivative) @ $0EDGAR
2021-05-134AFEYAN NOUBAR — Director, 10% ownerGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-03-234Flagship Ventures Fund IV General Partner LLC — 10% owner
Flagship Ventures Fund IV, L.P. — 10% owner
Flagship Ventures Fund V General Partner LLC — 10% owner
Flagship Ventures Fund V, L.P. — 10% owner
Flagship Ventures Opportunities Fund I General Partner LLC — 10% owner
Flagship Ventures Opportunities Fund I, L.P. — 10% owner
AFEYAN NOUBAR — Director, 10% owner
Purchase (P): 70,000 @ $29 · Purchase (P): 70,000 @ $29 · Purchase (P): 70,000 @ $29EDGAR
2021-03-154Keson-Brookes Maiken — CLO & Corp. SecretaryOption exercise (M): 25,000 @ $7.70 · Sale (S): 25,000 @ $20.24 · Option exercise (M): 25,000 (derivative) @ $0EDGAR
2021-02-164Epstein David R — DirectorSale (S): 26,704 @ $14.93EDGAR
2021-02-104Epstein David R — DirectorSale (S): 89,233 @ $14.88 · Sale (S): 2,100 @ $14.83 · Sale (S): 7,404 @ $14.79EDGAR
2021-02-024Coughlin Christina M. — Chief Medical OfficerGrant/award (A): 142,500 (derivative) @ $0 · Grant/award (A): 32,300 (derivative) @ $0EDGAR
2021-02-024Turka Laurence A. — Chief Scientific OfficerGrant/award (A): 131,250 (derivative) @ $0 · Grant/award (A): 29,750 (derivative) @ $0EDGAR
2021-02-024Keson-Brookes Maiken — CLO & Corp. SecretaryGrant/award (A): 142,500 (derivative) @ $0 · Grant/award (A): 32,300 (derivative) @ $0EDGAR
2021-02-024CAGNONI PABLO J — CEO and President, DirectorGrant/award (A): 375,000 (derivative) @ $0 · Grant/award (A): 85,000 (derivative) @ $0EDGAR
2020-12-024Carmona Jose — Chief Financial OfficerGrant/award (A): 400,000 (derivative) @ $0EDGAR

Recent 8-K events — Rubius Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-04-068-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2023-03-038-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2023-02-228-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-02-068-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2022-12-218-K2.01 — Completion of Acquisition or Disposition of AssetsEDGAR
2022-12-148-K1.02 — Termination of a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2022-12-128-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2022-11-028-K?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
EDGAR
2022-10-178-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2022-10-138-K2.04 — Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=RUBY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs